Brief: Burning Rock Announces An Exclusive In-Licensing Of Cancer Test
15/12/2020 06:37
Dec 15 (Reuters) - Burning Rock Biotech Ltd BNR.O :
* BURNING ROCK ANNOUNCES AN EXCLUSIVE IN-LICENSING OF A RISK
STRATIFICATION TEST FOR EARLY STAGE LUNG-CANCER PATIENTS FROM
ONCOCYTE IN CHINA
* ENTERED INTO EXCLUSIVE LICENSING AGREEMENT WITH ONCOCYTE
CORP
* AGREEMENT TO BRING LUNG CANCER TEST DETERMARX TO CHINA
Source text for Eikon: ID:nGNX4dt5hl
Further company coverage: BNR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Burning Rock Biotech
See all newsBurning Rock Biotech's Q2 revenue falls, net loss widens on central laboratory weakness
China's Burning Rock Biotech Q1 revenue falls on lower test volumes
China's Burning Rock Biotech Q4 net loss narrows as costs fall
Cancer diagnostics firm Burning Rock Biotech's Q3 revenue rises on pharma R&D growth
Brief: Burning Rock's Oncoguide™ Oncoscreen™ Plus CDX System Now Approved In Japan As A Companion Diagnostic For Capivasertib In Breast Cancer